(Renal) Report on Axitinib in Treatment-Naive Renal Cell Carcinoma Patients
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- November 10, 2016
- 1 min read
Published at ESMO 2016 by Dr. Brian I. Rini of the Cleveland Clinic in the United States, this retrospective analysis of Phase 2 and Phase 3 clinical trials of Axitinib (Inlyta) in treatment-naive renal cell carcinoma patients demonstrated high response rates, significant tumor reduction, and impressive overall survival (OS) outcomes.
In this trial, 402 patients were enrolled. The starting dose was 5 mg twice daily. At week 4, doses were escalated based on patient ECOG PS scores and tolerability—stepped up to 7 mg, and if well tolerated, further increased to 10 mg. The Phase 3 arm was stratified by ECOG PS, with an Axitinib group (5 mg twice daily) and a Sorafenib group (400 mg), randomized at a 2:1 ratio.
Of the 402 patients, 152 (37.8%) remained on treatment beyond 18 months, while 259 (62.2%) did not. Among the long-term cohort, 119 patients (29.6%) exceeded 2 years, 71 (17.7%) exceeded 3 years, and 28 (7.0%) exceeded 4 years. The median treatment duration was 34.7 months for those treated >18 months and 15 months for those treated ≤18 months.
Patients with longer treatment duration (>18 months) had favorable baseline characteristics: ECOG PS 0, normal ULN, good hemoglobin values, and no bone or liver metastases. Grade 3 or higher adverse events were more common in the >18-month group, including hypertension (25.7%), diarrhea (15.4%), and weight loss (11.2%).
Based on these data, long-term use of Axitinib did not reveal any new or unexpected safety signals.
Note: Image sourced from the Pfizer website, where additional information on this drug can be found.
Renal Cancer | Renal Cell Carcinoma
- Discovering the key to aggressive pancreatic cancer!
- New immune enhancers boosting cancer immunotherapy
- Kyoto University launches iPS cell cancer treatment!
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4